Abiopharma

News list

Ionis Pharmaceuticals Inc (IONS)

SEC News
Jan. 07, 2026, 11:02 UTC

(75% Positive) IONIS PHARMACEUTICALS, INC. (IONS) Provides Update on studies for bepirovirsen

Full text

News bot Jan. 7, 2026, 11:04 a.m.

📋 IONIS PHARMACEUTICALS, INC. (IONS) - Clinical Trial Update

Filing Date: 2026-01-07

Accepted: 2026-01-07 06:02:27

Event Type: Clinical Trial Update

Event Details:

Ionis Pharmaceuticals Inc (IONS) Announces Clinical Trial Update Ionis Pharmaceuticals Inc (IONS) provided an update on its clinical development programs. Clinical Development Highlights:

Drug Program: studies
Diseases/Conditions: bepirovirsen
Clinical Stage: Phase 3
Collaboration: CHB
Updated Timeline: Q1 2026

🔬 Clinical Development Pipeline (IONIS PHARMACEUTICALS, INC.):

Product	Type	Development Stage	Therapeutic Area	Source
Placebo	DRUG	Phase PHASE3	Angelman Syndrome	ClinicalTrials.gov
Donidalorsen	DRUG	Phase PHASE3	Hereditary Angioedema (HAE)	ClinicalTrials.gov
ION582	DRUG	Phase PHASE3	Angelman Syndrome	ClinicalTrials.gov
sapablursen	DRUG	Phase PHASE2	Phlebotomy Dependent Polycythemia Vera	ClinicalTrials.gov
Olezarsen	DRUG	Phase PHASE3	Familial Chylomicronemia Syndrome	ClinicalTrials.gov
ION356	DRUG	Phase PHASE1	Pelizaeus-Merzbacher Disease	ClinicalTrials.gov
Eplontersen	DRUG	Phase PHASE3	Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)	ClinicalTrials.gov
ION464	DRUG	Phase PHASE1	Multiple System Atrophy	ClinicalTrials.gov
Sham procedure	PROCEDURE	Phase PHASE1	Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome	ClinicalTrials.gov
ION440	DRUG	Phase PHASE1	Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome	ClinicalTrials.gov
zilganersen	DRUG	Phase PHASE3	Alexander Disease	ClinicalTrials.gov

💼 Business Developments:

Partnership
Acquisition: Not available
Licensing
Regulatory Approval
Executive Changes: Not available

Structured Data:

Company Name: Ionis Pharmaceuticals Inc
CIK: 0000874015
Ticker Symbol: IONS
Period End Date: 2026-01-07
Document Type: 8-K